These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30797713)
41. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420 [TBL] [Abstract][Full Text] [Related]
42. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283 [TBL] [Abstract][Full Text] [Related]
43. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
50. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors]. Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316 [TBL] [Abstract][Full Text] [Related]
51. Low-grade serous ovarian cancer: State of the science. Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252 [TBL] [Abstract][Full Text] [Related]
52. Overexpression of tyrosine kinase receptor B promotes metastasis of ovarian serous adenocarcinoma by lymphangiogenesis. Zheng W; Dai Q; Tao P; Sun A; Wang Y; Bao L; Zhang G Tumori; 2011; 97(6):756-61. PubMed ID: 22322843 [TBL] [Abstract][Full Text] [Related]
53. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study. Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178 [TBL] [Abstract][Full Text] [Related]
54. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054 [TBL] [Abstract][Full Text] [Related]
55. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832 [TBL] [Abstract][Full Text] [Related]
56. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453 [TBL] [Abstract][Full Text] [Related]
57. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362 [TBL] [Abstract][Full Text] [Related]
58. A case of ovarian serous adenocarcinoma suggestive of transformation to an AFP-producing tumor during chemotherapy. Kataoka A; Nishida T; Sugiyama T; Yakushiji M J Obstet Gynaecol (Tokyo 1995); 1995 Oct; 21(5):451-9. PubMed ID: 8542468 [TBL] [Abstract][Full Text] [Related]
59. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]